Midterm results of mitral valve repair with lifting annuloplasty strip for acute phase infective endocarditis

Sung Jun Lee¹, Hyun Suk Yang²*, Jun Seok Kim¹, Je Kyoun Shin¹, Jae Sung Son³, Meong Gun Song¹ and Hyun Keun Chee¹

Abstract

Background: Mitral valve repair is favored over replacement due to superior outcomes. However, extensive infective endocarditis (IE) often has been considered unreconstructable. We retrospectively analyzed the mid-term outcomes of an individualized repair approach using a lifting annuloplasty strip.

Methods: Between December 2007 and March 2014, 27 consecutive patients with acute single mitral valve IE (age 43 ± 16 years, 11 men) underwent lifting mitral annuloplasty (LMA) with a strip (Mitracon® strip, 28 mm in 4, 32 mm in 10, and 34 mm in 13). Blood culture was positive in 70 % (Streptococcus 10, Staphylococcus 4, HACEK 3, Enterococcus 1, Gram negative bacilli 1). One case (4 %) had a previously repaired mitral valve—the repair was redone. Via right thoracotomy (74 %) or median sternotomy (26 %), repair was performed by removal of vegetation and resection of infected tissue, the defect typically then being repaired using a bovine pericardial patch (81 %). Artificial chordae were formed in 5 patients. Nine (33 %) of them had posterior leaflet augmentation (PLA) to get sufficient coaptation height. Clinical and echocardiographic follow-up were performed.

Results: Compared with preoperative ones, postoperative echocardiograms revealed decreases of left ventricular (LV) end-diastolic dimensions (57.2 ± 6.3 versus, 45.4 ± 6.2, or 44.8 ± 4.1 mm, all p < 0.01). The LV ejection fraction decreased immediately, but recovered (64.4 ± 9.6 % vs. 54.5 ± 9.8 %, or 65.2 ± 6.1 %, p = 0.002, p = 1.000, respectively). The latest follow-up echocardiograms (median 28 months) universally showed no or minimal regurgitation, with a preserved mitral valve opening area (2.27 ± 0.48 cm²). During the clinical follow-up (median, 54 months), one (3.7 %) death was observed (in-hospital, due to biliary sepsis and pneumonia). There was no reoperation or major cardiovascular event. The 5 year survival rate was 96.3 %.

Conclusions: The repair technique of LMA and/or PLA in patients with IE achieved good structural and functional outcomes as well as an excellent 5 year survival rate. An individualized repair approach should be recommended in patients with acute phase IE.

Keywords: Endocarditis, Mitral Valve Insufficiency, Repair Material

* Correspondence: yang.hyun@gmail.com
²Department of Cardiovascular medicine, Konkuk University Medical Center, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, South Korea

© 2015 Lee et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite advanced diagnostic modalities and therapeutic techniques, infective endocarditis (IE) remains a dangerous condition with an incidence ranging from 16 to 62 cases per million person-years [1]. Treatment for IE consists of antibiotic therapy or surgery, or both. Most patients receive a total of 6 weeks of antibiotics therapy regardless of the timing of surgery [2]. Indications for surgical treatment in patients with IE include congestive heart failure, periannular extension of IE, systemic embolism, cerebrovascular complications, persistent sepsis, and large vegetations with a risk of embolization [3].

In the setting of degenerative mitral valve regurgitation, mitral valve repair is preferred over mitral valve replacement, but for treatment of mitral regurgitation due to IE, mitral valve replacement is preferred because of concerns about the durability of mitral valve repair, recurrence of IE, and mitral regurgitation [4–7]. But recent published clinical trials have suggested that mitral valve repair may be feasible and offer better survival compared with mitral valve replacement even in patients undergoing surgery for IE [1, 8, 9].

The aim of the present single-center, consecutive patient study is to investigate the outcomes of mitral valve repair using lifting mitral annuloplasty (LMA) during acute phase IE having extensive destruction of the mitral valve.

Methods
Study population
The Konkuk University Medical Center Institutional Review Board approved this retrospective study and waived the need for individual patient consent. The clinical records of patients who underwent mitral valve surgery for IE were reviewed from December 2007 to March 2014. A total 39 mitral valve open heart surgeries were performed during the study period for correction of acute phase IE in the mitral valve. Among them, there were 29 single mitral valve surgeries, the rest double valve, including the aortic valve. Of the 29 cases, two patients underwent mitral valve replacement—one underwent prior open heart surgery for mitral valve replacement and MAZE for rheumatic mitral valve stenosis and atrial fibrillation, the other underwent mitral valve repair for unknown etiology elsewhere. The study cohort of single mitral valve repairs due to acute phase IE therefore comprised 27 consecutive patients. The mean age was 43 ± 16 years (range, 21–81), the baseline characteristics are summarized in Table 1.

Acute phase endocarditis was clinically diagnosed by the modified Duke criteria [10], and surgically confirmed in the entire study population. Nineteen patients (70 %) were blood culture-positive IE. The most common microorganisms were Streptococcus in 11 patients (58 %)—Streptococcus mitis in 4, Streptococcus sanguinis in 2, Other

| Table 1 Preoperative characteristics of the 27 patients who underwent lifting mitral annuloplasty |
|-----------------|-----------------|
| Variables       | No. (%)         |
| Age (years)     | 43 ± 16         |
| Male            | 11 (41)         |
| Indication for surgery (≥ moderate to severe MR) and, |                     |
| Systemic embolism with large vegetations | 12 (44)         |
| Heart failure with acute pulmonary edema      | 7 (26)          |
| Septic shock   | 3 (11)          |
| Persistent fever and positive blood cultures > 7 to 10 days | 1 (4)           |
| LV EF (%)      | 64.4 ± 0.36     |
| MR ERO (cm²)   | 0.59 ± 0.30     |
| Positive blood culture                          |                 |
| Streptococcus  | 11              |
| Mitis          | 4               |
| Sanguinis      | 2               |
| Viridans       | 2               |
| Pneumoniae     | 1               |
| Gordoni        | 1               |
| Enterococcus femailis                           | 1               |
| Staphylococcus | 4               |
| MRSA           | 3               |
| MSSA           | 1               |
| HACEK group    | 3               |
| Gram negative bacilli                            | 1               |
| Valvular pathology                                |                 |
| Native mitral valve                               | 26 (96)         |
| Myxomatous, prolapse                              | 10              |
| Ruptured chordae                                  | 9               |
| Rheumatic                                             | 4               |
| Unclear, destructed by vegetations                | 3               |
| Status post mitral valve repair, elsewhere         | 1 (4)           |

MR Mitral regurgitation, LV EF Left ventricular ejection fraction, ERO Effective regurgitant orifice, MRSA Methicillin- resistant Staphylococcus aureus, MSSA Methicillin-sensitive Staphylococcus aureus, HACEK Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella

Viridans streptococci in 2, Streptococcus pneumoniae in 1, Streptococcus gordonii in 1, and Enterococcus femailis in 1. Next were Staphylococcus in 4 (21 %) (Methicillin-resistant Staphylococcus aureus [MRSA] in 3, and Methicillin-sensitive Staphylococcus aureus in 1), the Haemophilus parainfluenzae in 3 (16 %), and other gram-negative bacilli in 1 (5 %). Culture-negative endocarditis was defined as endocarditis in which no microorganism could be identified either on serial blood culture or in cultures made from the explanted valvular tissue of patients presenting with the clinical picture of endocarditis. Its presentation was significant with systemic embolism in 12 patients (44 %): embolic stroke was the first
presentation in 9 patients, and there were other combined systemic embolic infarctions in the spleen (2 patients), kidney (one patient), or other peripheral extremities (2 patients). The presentation with acute heart failure with acute pulmonary edema was 26 % and with septic shock, 11 %. The preoperative chest X-ray revealed pulmonary edema in 7 patients while electrocardiograms showed atrial fibrillation in 3 patients (paroxysmal atrial fibrillation in 1).

The preoperative echocardiograms showed a mean left ventricular (LV) ejection fraction (EF) of 64.4 ± 9.6 % (range, 35–79 %). One patient had prior mitral valve ring annuloplasty elsewhere, and the others showed native mitral valves with leaflet prolapse or chordae rupture, and suspicious underlying rheumatic pathologies (4 patients). The mitral vegetations were extensive in both anterior and posterior leaflets in 15 patients, mainly anterior in 9 patients, and posterior in 3 patients. The amount of mitral valve regurgitation was moderate or severe with an effective regurgitant orifice (ERO) of 0.59 ± 0.30 cm² by the proximal isovelocity surface area method [11].

### Timing of surgery

The timing for surgery varied. The median period from admission to operation was 4 days (interquartile range, 1–9). As a referral center, the actual interval from diagnosis to operation was 20.9 ± 14.0 days, and according to the culture-driven antimicrobial therapy [12] preoperative intravenous antibiotics were prescribed for 21.0 ± 13.6 days.

### Operative procedure

Right anterolateral thoracotomy, as a standard approach of surgery for mitral valve regurgitation in our center, was performed in 74 % (20/27) of patients. Under general anesthesia with double-lumen intubation, patients were positioned in left decubitus. Cardiopulmonary bypass was initiated using peripheral cannulation through the right internal jugular vein, right femoral vein, and right femoral artery, under transesophageal echocardiography guidance. Median sternotomy was performed in 26 % (7/27) of patients who had obstructive or restrictive lung disease on the pulmonary function test (such as measuring forced expiratory volume in less than 1 s) or who underwent cardiac surgery via right thoracotomy previously. All operations were performed using a standard cardiopulmonary bypass with crystalloid cardioplegia and mild hypothermia. Operative data are summarized in Table 2.

All mitral valve repairs were performed through the left atrium via the groove of Sondergaard. All the visible vegetations and infected tissues were eliminated. In 22 patients (81 %), including the 3 patients with a previous perforation from destructive IE, the ruptured hole in mitral valve leaflets formed by the removal of vegetation or slicing of the leaflet was repaired with bovine pericardium (Supple Peri-guard® bovine pericardium repair patch, 6 cm × 8 cm, Synovis® Surgical, Jisang International, Inc.). Chordal replacement with expanded polytetrafluoroethylene sutures was performed in 5 (19 %) patients, posterior leaflet augmentation (PLA) in 9 (33 %) [13]. As the final step, in all patients, LMA was performed using a mitral strip (Mitracon®, ScienCity Co., Seoul, Korea), flat and flexible polyethylene terephthalate, 5 mm wide with two thick margins and a thin gully between them [14]. The LMA technique was described in detail previously [14]. Interrupted mattress sutures of non-absorbable multifilament material are placed in the posterior mitral annulus, beginning at the anterolateral commissure to posteromedial commissure. Six sutures are generally required. The difference from typical annular sutures is the placement: in LMA, annular sutures pass through the left atrial (LA) wall above the posterior mitral annulus, going slightly through the annulus and then out through LA wall. This type of suture has the effect of lifting the posterior annulus to the LA side. Since 2007, our institution has performed this type of annular suture. In 9 (33 %) patients, to achieve a sufficient coaptation length (≥5 mm) to prevent development of mitral regurgitation, PLA was performed using an elliptical pericardial patch [15]. Other concomitant cardiac procedures were performed in 4 patients (15 %), including the maze procedure, tricuspid annuloplasty, and the direct closure of patent foramen ovale.

### Table 2 Operative data

| Variables | No. (%) |
|-----------|---------|
| Approach  |         |
| Right thoracotomy | 20 (74) |
| Left thoracotomy | 7 (26)  |
| Repair techniques |         |
| Lifting annuloplasty with a strip | 27 (100) |
| Leaflet patching repair | 22 (81) |
| Posterior leaflet augmentation | 9 (33)  |
| Artificial chordae formation | 5 (19)  |
| Lifting annuloplasty strip size |         |
| 28 mm | 4 (15) |
| 32 mm | 10 (37) |
| 34 mm | 13 (48) |
| Concomitant procedure |         |
| Cox-Maze procedure | 2 |
| Tricuspid annuloplasty | 1 |
| Direct closure of persistent foramen ovale | 1 |
Post-operative antibiotic therapy
In patients with a positive operative tissue culture (two cases, MRSA, *Enterococcus faecalis*), full coverage of antimicrobial therapy was given, starting from the time of surgery; however, in most patients with a negative operative tissue culture, the duration of antimicrobial therapy was calculated from the preoperative antibiotics for 4 to 6 weeks, and minimum one week of post-operative period even if the duration extended the overall course. The duration of postoperative antibiotic therapy was 22.4 ± 11.1 days.

**Statistical analysis**
Statistical analysis was performed with dBSTAT (DBSTAT Version 5. Chuncheon, Korea: DBSTAT Co.; 2010. http://dbstat.com). Baseline and follow-up data were expressed as mean (standard deviation) or median (interquartile range) for continuous variables and as a number (percentage) for categorical or binary variables. All continuous data were tested for a normal distribution using Kolmogorov-Smirnov nonparametric tests. Sphericity was tested using Mauchly’s test. Serial echocardiographic changes were assessed using a repeated measures analysis of variance. Post hoc analyses were performed using Bonferroni’s method. The cumulative event-free survival curve was determined according to the Kaplan-Meier method. Two-sided p values < 0.05 were considered statistically significant.

**Results**
**General outcomes**
The median postoperative follow-up duration was 54.1 months. The overall mortality rate was 3.7 % (1 of 27): a 72-year-old woman died from septic shock caused by cholangitis, pancreatitis, and pneumonia, and had a pre-existing diagnosis of stomach cancer—despite good immediate-postoperative cardiac function. None of the patients experienced valve-related complications such as thromboembolism bleeding events associated anticoagulation. During the follow-up, there was no recurrence of endocarditis and no reoperation. The 5 year survival rate was 96.3 %.

**Immediate-postoperative echocardiographic results**
Comprehensive transthoracic echocardiography was performed before patient discharge, the mean postoperative period being 7.4 ± 2.4 days. Immediately postoperatively, all patients showed mitral regurgitation less than grade 1. The LV end-diastolic dimension (EDD) and LV end-systolic dimension (ESD) decreased from 57.2 ± 6.3 to 45.4 ± 6.2 mm (p < 0.001) and from 35.7 ± 6.7 to 28.3 ± 2.9 mm (p < 0.001). The decreased LV EF in the immediate postoperative period improved from 54.5 ± 9.8 % to 65.2 ± 6.1 % (Fig. 1). The LA dimension and estimated PASP persistently decreased from 46.5 ± 5.9 to 35.3 ± 9.6 mm (p < 0.001) and from 26.9 ± 5.1 mmHg (p = 0.012). The mean mitral valve area measured by two-dimensional area was 2.27 ± 0.48 cm² at the last follow-up visit. The echocardiographic findings are summarized in Table 3 and Fig. 1.

**Discussion**
Mitral valve repair is a standard treatment for noninfected valvular disease. One of the advantages of mitral valve repair over mitral valve replacement is the preservation of LV function. Kouris and associates reported that mitral valve repair in patients with mitral regurgitation achieved better preservation of LV systolic indices than mitral valve replacement, probably due to preservation of the subvalvular apparatus and LV geometry [16], and several studies have suggested better survival and freedom from anticoagulant related hemorrhage, thromboembolism, and endocarditis [17, 18]. For these reasons, mitral valve repair is preferred to valve replacement in patients with degenerative mitral valve disease. Already the use of mitral valve repair has exceeded the use of replacement. Gammie et al. demonstrated that the rate of mitral valve repair versus replacement increased from 51 to 69 % and that operative risks of mitral valve repair were significantly lower than those for mitral valve replacement [19]. Barnett et al. reported that the surgical treatment for mitral disease has transitioned to primarily one of repair, not replacement [20]. But valvular replacement has been performed only infrequently for patients with mitral valve endocarditis because of the fragile valvular apparatus and concerns about recurrent IE and mitral valve plasty durability. Gammie et al. reported a 20 and 48 % feasibility rate of mitral valve repair in active and healed endocarditis respectively [8].

The most recent reports suggest acceptable short- and long-term outcomes. Ruttmann et al. demonstrated that event-free survival at 1 year was 88.2 and 80.4 % at
5 years in the repair group [4]. Miura et al. reported that 4-year survival was 88.2 % and the 4-year reoperation-free rate was 92.4 % in the repair group [21]. Shimokawa et al. reported that freedom from moderate or severe MR was 91.9 % ± 1.5 % and 83.3 % ± 2.3 % at 10 years [5]. Zegdi et al. reported that the 10-year survival rate and freedom from mitral valve reoperation were 80 and 91 %, respectively [7]. In our series, the overall mortality rate was 3.7 % (1 of 27) and the 5 year survival rate was 96.3 %.

In active endocarditis, the feasibility of valve repair depends on the extent of the pathological lesion [22]. In published studies, the feasibility of repairing infected mitral valves for acute endocarditis has been demonstrated to vary from 33 to 78 % [1]. Iung et al. reported that MV repair was feasible in 81 % of patients; 19 % of patients underwent MVR because of the extent of tissue destruction [23]. In our study, among the consecutive patients who underwent open heart surgery due to single mitral valve IE, only two patients (2 of 29) had replacements, both of them re-doing prior mitral valve operations. The extent of pathological lesions seemed not to restrict the choice for repair over replacement—most (15 of 27) involved both anterior and posterior leaflets, with the clinical and echocardiographic findings showing favorable outcomes.

Although an important surgical rule when dealing with valve surgery due to IE is to avoid the use of prosthetic material as often as possible, in our case, using the LMA strip with or without bovine pericardium to reconstruct the mitral valve defect, there was no recurrent endocarditis during the median follow-up of 54 months. The reported recurrence rates of endocarditis in patients undergoing mitral valve repair for active endocarditis were as low as 1 in 37 patients [7]. In our study, we do not confirm that the mitral strip was tolerant of infection, but we believe that our novel technique of LMA with a strip, with or without PLA, helped to increase the reconstructibility in active endocarditis as to 27 of 29 (93 %), which overall helps reduce the recurrence of endocarditis in surgically treated active IE. Radical

![Fig. 1 Serial changes of echocardiographic parameters: preoperative, median 7 days, and median 30 months after lifting mitral annuloplasty (T0, T1, and T2, respectively). a Left ventricular end-diastolic dimension (LV EDD, mm); b Left ventricular end-systolic dimension (LV ESD, mm); c Left ventricular ejection fraction (LV EF, %); d Left atrial dimension (LAD, mm); e Estimated pulmonary arterial systolic pressure (PASP, mm Hg) from tricuspid regurgitation peak velocity with estimated right atrial pressure. CI, Confidence interval. *P < 0.05, T0 versus T1 and T2, †P < 0.05, T1 versus T2, by post hoc Bonferroni’s test]
debridement of infective tissue followed by local antibiotic irrigation and fully maintained intravenous antibiotic therapy for 4–6 weeks are, we believe, important concomitants in preventing recurrence of IE [24].

In patients with rheumatic valve pathology such as shrunken or thickened leaflets, we sliced the leaflet to increase pliability and then augmented the posterior leaflet using bovine pericardium. This technique has been described by Chauvaud et al. [13]. We used a bovine pericardium because the use of this material has been shown to be more cost-effective although no data are available on the long-term results of the use of bovine pericardium—longer follow-up is essential.

The normal mitral annulus is not a two-dimensional flat and fixed structure but rather takes the three-dimensional form of a saddle [25]. The saddle shape has been accentuated from late diastole to early systole in the normal annulus but this change is blunted in mitral valve disease [26]. This shape has been shown to reduce stress on the mitral leaflet, an important determinant of durability after mitral valve repair [27]. Our lifting annuloplasty was based on this concept. Anatomically, the anterior mitral annulus attaches to the fibrous skeleton at the base of the heart and is more rigid; the posterior annulus is thinner and more susceptible to dilatation [28]. With LMA, annular sutures go through the LA wall above the posterior mitral annulus, then slightly go through the annulus and out through LA wall. This annular suture technique has the effect of lifting the posterior annulus to the LA side and increasing the annulus three-dimensional curvature. In this study, in patients with active IE, repair of mitral valve using LMA with or without PLA reveals good outcomes with an acceptable coaptation of both mitral leaflets.

A decrease in atrial and ventricular size, called reverse remodeling, has been observed after mitral valve procedures. In our study, the immediate postoperative LV EF was decreased but recovered after follow-up. This phenomenon may be because the LV EDD is reduced more quickly than the LV ESD, resulting in a decreased LV EF; however, the negative remodeling of the LV ESD restored the LV EF (Fig. 1). These findings mean that reverse remodeling may need significant time.

Limitations
This is a single-center experience with a relatively small number of patients. Our study excluded patients having mitral valve replacement in order to focus on the effects of our techniques on mitral valve repair with endocarditis per se, and comparison between mitral valve repair and replacement was limited due to only 2 patients undergoing replacement. Finally, we are aware that the lack of comparison with other repair techniques limits conclusions concerning the superiority of the LMA approach. However, repair techniques using bovine pericardium and LMA has enabled us to suggest that extensive IE is not a strong contraindication for mitral valve repair. Further studies incorporating a larger number of patients and

| Table 3 Post-operative echocardiographic findings |
|-----------------------------------------------|
|                  | Pre-operative | Post-operative | Last follow-up | P value* |
| Follow-up duration |               | 7.4 ± 2.4 days | 30 ± 22 months |         |
| MR ERO (cm²)      | 0.59 ± 0.30   |                |               |         |
| MR grade 0 ~ I    | 3.68 ± 0.50   | 0.1 ± 0.2      | <0.001        | 0.37 ± 0.22 |
| II                | 1             | 0              |               | <0.001 |
| III               | 4             | 0              |               | <0.001 |
| IV                | 22            | 0              |               |         |
| MVA, 2D (cm²)     |                | 2.27 ± 0.48    |               |         |
| LV EF (%)         | 64.4 ± 9.6    | 54.5 ± 9.8*    | 0.002         | 65.2 ± 6.1** |
| LV EDD (mm)       | 57.2 ± 6.3    | 45.4 ± 6.2*    | <0.001        | 44.8 ± 4.1* |
| LV ESD (mm)       | 35.7 ± 6.7    | 32.5 ± 6.3*    | 0.046         | 28.3 ± 2.9*** |
| LAD (mm)          | 46.5 ± 6.0    | 35.4 ± 6.3*    | <0.001        | 36.6 ± 6.8* |
| PASP (mmHg)       | 37.5 ± 14.2   | 24.5 ± 6.6*    | <0.001        | 26.7 ± 5.0* |

MR mitral regurgitation, ERO effective regurgitant orifice, MVA mitral valve area, 2D two-dimensional, LV left ventricular, EF ejection fraction, EDD end-diastolic dimension, ESD end-systolic dimension, LAD left atrial dimension, PASP pulmonary artery systolic pressure estimated by tricuspid regurgitation peak velocity with right atrial pressure

*compared with preoperative
**P < 0.01, immediate after versus last follow-up
comparable groups using other repair techniques are necessary to evaluate the relative advantages of our mitral valve repair techniques.

**Conclusion**

This repair technique of LMA with or without PLA in patients with acute-phase IE achieved good structural and functional outcomes as well as an excellent 5 year survival rate. An individualized repair approach should be recommended in patients with acute-phase IE.

**Abbreviations**

EDD: End-diastolic dimension; EF: Ejection fraction; ERO: Effective regurgitant orifice; ESD: End-systolic dimension; IE: Infective endocarditis; LA: Left atrial; LMA: Lifting mitral annuloplasty; LV: Left ventricular; PASP: Pulmonary artery systolic pressure; PLA: Posterior leaflet augmentation.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

SJL, HSY, HKC performed the study. JSK, JKS, JSS and HKC provided critical review. SJL wrote the manuscript. HSY, JSS collected the data and helped to draft the manuscript. HSY performed most of the echocardiographic evaluation. JSK, JKS, JSS and HKC provided critical review. All authors read and approved the final manuscript.

**Acknowledgements**

This work was supported by Konkuk University.

**Author details**

1Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, South Korea. 2Department of Cardiovascular medicine, Konkuk University Medical Center, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, South Korea. 3Department of Pediatric Cardiology, Konkuk University Medical Center, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, South Korea.

**Received:** 25 May 2015  **Accepted:** 28 October 2015  **Published online:** 31 October 2015

**References**

1. Feringa HH, Shaw LJ, Poldermans D, Hoeks S, van der Wall EE, Dion RA, et al. Mitral valve repair and replacement in endocarditis: a systematic review of literature. Ann Thorac Surg. 2007;83(2):564–70.
2. Hoen B, Duval X. Clinical practice: Infective endocarditis. N Engl J Med. 2013;368(15):1425–33.
3. Prendergast BD, Tornos P. Surgery for infective endocarditis: who and why? Circulation. 2010;121(9):1141–52.
4. Ruttmann E, Legit C, Poelzl G, Mueller S, Chevtchik O, Cottogni M, et al. Mitral valve repair provides improved outcome over replacement in active infective endocarditis. J Thorac Cardiovasc Surg. 2005;130(3):765–71.
5. Shimokawa T, Kasegawa H, Matsuyama S, Seki H, Marabe S, Fukushima G, et al. Mitral valve repair outcomes of mitral valve repair for infective endocarditis. Ann Thorac Surg. 2009;88(3):733–9.
6. Yamaguchi H, Eishi K, Yamachika S, Hisata Y, Tanigawa K, Izumi K, et al. Mitral valve repair in patients with infective endocarditis. Circ J. 2006;70(2):179–83.
7. Zegli R, Debieche M, Latremouille C, Lebled D, Chardigny C, Grinda JM, et al. Long-term results of mitral valve repair in active endocarditis. Circulation. 2005;111(19):2532–6.
8. Gimme JS, O’Brien SM, Griffith BP, Peterson ED. Surgical treatment of mitral valve endocarditis in North America. Ann Thorac Surg. 2005;80(6):2199–204.
9. Hisatomi K, Yamaeda T, Odate T, Yamashita K, Eishi K. Mitral valve repair during acute phase infective endocarditis with extensive destruction of the anterior leaflet rough zone and cerebral infarction. Gen Thorac Cardiovasc Surg. 2012;60(8):507–10.
10. Li JS, Sexton DJ, Mick N, Nettles R, Fowler Jr VG, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–8.
11. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, KAAD CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802.
12. Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(12):1394–434.
13. Chauvaud S, Jebraa V, Chaqueux JC, de Asmar B, Mihaleanu S, Perier P, et al. Surgical treatment of infective endocarditis: results in mitral valve repair. J Thorac Cardiovasc Surg. 1991;102(2):171–7.
14. Choi JB, Kim KH, Kim MH, Kim WH. Improvement of mitral valve coaptation with supraannular plication of the posterior annulus–a newly designed strip for posterior annular plication. Ann Thorac Cardiovasc Surg. 2012;18(9):595–600.
15. Choi JB, Kim KH, Kim MH, Kim WH. Mitral valve re-repair in an adolescent patient with prosthetic ring endocarditis: posterior leaflet augmentation and posterior strip annuloplasty. J Card Surg. 2012;27(5):560–2.
16. Kouris N, Ikonomidou J, Kontogianni D, Smith P, Nihoyannopoulos P. Mitral valve repair versus replacement for isolated non-ischemic mitral regurgitation in patients with preoperative left ventricular dysfunction. A long-term follow-up echocardiography study. Eur J Echocardiogr. 2005;6(6):435–42.
17. Braunberger E, Deloche A, Béréde A, Abdallah C, Celestin JA, Meimoun P, et al. Very long-term results (more than 20 years) of valve repair with carpenter’s techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104(12 Suppl 1):I8–111.
18. David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg. 2005;130(5):1242–9.
19. Gimme JS, Sheng S, Griffith BP, Peterson ED, Rankin JS, O’Brien SM, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87(5):1431–7.
20. Barnett SD, Ad N. Surgery for aortic and mitral valve disease in the United States: a trend of change in surgical practice between 1998 and 2005. J Thorac Cardiovasc Surg. 2009;137(6):1422–9.
21. Miura T, Hamawaki M, Hazama S, Hashizume K, Eishi K, Yamashita K, et al. Outcome of surgical management for active mitral native valve infective endocarditis: a collective review of 57 patients. Gen Thorac Cardiovasc Surg. 2014;62(8):488–98.
22. Yamaguchi H, Eishi K, Surgical treatment of active infective mitral valve endocarditis. Ann Thorac Cardiovasc Surg. 2007;13(3):150–5.
23. Jung B, Rousseau-Paizaud J, Corrier J, Garbarz E, Fournier O, Brochet E, et al. Contemporary results of mitral valve repair for infective endocarditis. J Am Coll Cardiol. 2004;43(3):386–92.
24. Weymann A, Borst T, Popov AF, Sabashnikov A, Bowlus C, Schmack B, et al. Surgical treatment of infective endocarditis in active intravenous drug users: a justified procedure? J Cardiothorac Surg. 2014;9:58.
25. Komoda T, Hara K, Suzuki S, Iwata H, Yasuda R, Hoerndahl UP, et al. Mitral annular function assessment by 3D imaging for mitral valve surgery. J Heart Valve Dis. 1994;3(5):483–90.
26. Grevel J, Suri R, Mankad S, Tanaka A, Mahoney DW, Schiff HH, et al. Mitral annular dynamics in myxomatous valve disease: new insights with real-time 3-dimensional echocardiography. Circulation. 2010;121(12):1423–31.
27. Gillinov AM, Cosgrove DM, Blackstone EH, Diaz R, Arnold JH, Lytle BW, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg. 1998;116(5):734–43.